Loading...
OTCM
VCNX
Market cap1mUSD
Jun 02, Last price  
0.72USD
1D
-22.12%
1Q
-37.91%
IPO
-99.58%
Name

Vaccinex Inc

Chart & Performance

D1W1MN
P/E
P/S
3.38
EPS
Div Yield, %
Shrs. gr., 5y
79.51%
Rev. gr., 5y
-4.67%
Revenues
570k
+470.00%
316,00090,000724,000523,00050,000900,000100,000570,000
Net income
-20m
L+2.68%
-13,943,000-18,722,000-29,518,000-32,015,000-29,309,000-23,232,000-19,722,000-20,251,000
CFO
-17m
L-9.65%
-19,720,000-21,387,000-25,276,000-30,715,000-28,647,000-25,298,000-19,074,000-17,234,000
Earnings
Aug 12, 2025

Profile

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
IPO date
Aug 09, 2018
Employees
38
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
570
470.00%
100
-88.89%
Cost of revenue
23,455
20,388
Unusual Expense (Income)
NOPBT
(22,885)
(20,288)
NOPBT Margin
Operating Taxes
(93)
Tax Rate
NOPAT
(22,885)
(20,195)
Net income
(20,251)
2.68%
(19,722)
-15.11%
Dividends
Dividend yield
Proceeds from repurchase of equity
12,519
17,050
BB yield
-4,061.52%
-872.74%
Debt
Debt current
367
238
Long-term debt
172
557
Deferred revenue
Other long-term liabilities
Net debt
(996)
(5,596)
Cash flow
Cash from operating activities
(17,234)
(19,074)
CAPEX
(67)
(99)
Cash from investing activities
(67)
(99)
Cash from financing activities
12,445
16,975
FCF
(20,468)
(20,256)
Balance
Cash
1,535
6,391
Long term investments
Excess cash
1,506
6,386
Stockholders' equity
(339,927)
(319,671)
Invested Capital
338,009
325,349
ROIC
ROCE
1,193.17%
EV
Common stock shares outstanding
464
202
Price
0.66
-93.12%
9.67
-38.03%
Market cap
308
-84.22%
1,954
-8.84%
EV
(688)
(3,642)
EBITDA
(22,766)
(20,081)
EV/EBITDA
0.03
0.18
Interest
1,000
2
Interest/NOPBT